Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA065910-01A2
Application #
2008695
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1996-09-30
Project End
1999-07-31
Budget Start
1996-09-30
Budget End
1997-07-31
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Zhang, Hao; Shao, Huanjie; Golubovskaya, Vita M et al. (2016) Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways. Br J Cancer 115:203-11
Wilton, John; Kurenova, Elena; Pitzonka, Laura et al. (2016) Pharmacokinetic analysis of the FAK scaffold inhibitor C4 in dogs. Eur J Drug Metab Pharmacokinet 41:55-67
Marlowe, Timothy A; Lenzo, Felicia L; Figel, Sheila A et al. (2016) Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-Kinase Inhibitors. Mol Cancer Ther 15:3028-3039
Stewart, Jerry E; Ma, Xiaojie; Megison, Michael et al. (2015) Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma. Mol Carcinog 54:9-23
Golubovskaya, Vita; Curtin, Leslie; Groman, Adrienne et al. (2015) In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride). Arch Toxicol 89:1095-101
Dy, Grace K; Ylagan, Lourdes; Pokharel, Saraswati et al. (2014) The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer. J Thorac Oncol 9:1278-84
Golubovskaya, Vita M (2014) Targeting FAK in human cancer: from finding to first clinical trials. Front Biosci (Landmark Ed) 19:687-706
Huang, Grace; Ho, Baotran; Conroy, Jeffrey et al. (2014) The microarray gene profiling analysis of glioblastoma cancer cells reveals genes affected by FAK inhibitor Y15 and combination of Y15 and temozolomide. Anticancer Agents Med Chem 14:9-17
O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59
Ho, Baotran; Huang, Grace; Golubovskaya, Vita M (2014) Focal adhesion kinase regulates expression of thioredoxin-interacting protein (TXNIP) in cancer cells. Anticancer Agents Med Chem 14:3-8

Showing the most recent 10 out of 62 publications